Johnson & Johnson has added another piece to the data behind its effort to move Tecvayli into earlier-line therapy for multiple myeloma, including the first relapse setting. In the MajesTEC-9 trial, ...
A $292 million exploit and $13 billion TVL drop looks catastrophic on the surface, but the data tells a different story.
Daniel Liberto is a journalist with over 10 years of experience working with publications such as the Financial Times, The Independent, and Investors Chronicle. David Kindness is a Certified Public ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results